Previous 10 | Next 10 |
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES PR Newswire NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
2023-09-27 16:30:10 ET Summary Biohaven's stock surged nearly 30% following updates on its preclinical asset, the IgA degrader BHV-1300. The company's stock has risen more than 270% since its spinout from parent company Biohaven Pharmaceutical. Biohaven's preclinical pipeline ...
2023-09-27 13:48:39 ET Gainers: ShiftPixy ( PIXY ) +92% . SciSparc Ltd ( SPRC ) +42% . MSP Recovery ( LIFW ) +41% . Biohaven ( BHVN ) +28% . MillerKnoll ( MLKN ) +28% . American Strategic Investment Co ( NYC ) +22% . ...
2023-09-27 12:00:40 ET Shares of Biohaven (NYSE: BHVN) skyrocketed by 28.2% as of 11:10 a.m. ET Wednesday after the biopharmaceutical company submitted a regulatory filing to the Securities and Exchange Commission that included a new investor presentation. The big news in that n...
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is one of today's top gainers. The company's shares are currently up 30.31% on the day to $23. Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsych...
2023-09-27 09:46:22 ET More on Biohaven Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven falls as FDA rejects filing for movement disorder therapy Seeking Alpha’s Quant Rating on Biohaven Historical earnings data for Biohave...
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy PR Newswire - Taldefgrobep alfa is the only myostatin inhibitor in clinical development that targets both myostatin and activin A signaling, two key regulators of muscle mass...
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies PR Newswire Examination of EEG in healthy subjects administered single...
2023-09-02 12:00:00 ET Summary The decelerating COVID-19 portfolio and underperforming bolt-on acquisitions have directly contributed to PFE's lowered FY2023 guidance range. In an attempt to boost its pipeline, thanks to the patent cliff from 2025 onwards, the company has also emb...
2023-08-28 02:26:53 ET Summary Biohaven faces FDA rejection for troriluzole; explores further discussions and potential subgroup focus. Despite FDA setback, Biohaven maintains a strong cash position, diversified pipeline, and ongoing R&D efforts. Given current uncertaintie...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...